Standard BioTools Inc.
LAB
$1.18
$0.098.26%
| Weiss Ratings | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.02 | |||
| Price History | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.61% | |||
| 30-Day Total Return | -15.11% | |||
| 60-Day Total Return | -35.16% | |||
| 90-Day Total Return | -21.85% | |||
| Year to Date Total Return | -32.57% | |||
| 1-Year Total Return | -55.30% | |||
| 2-Year Total Return | -37.89% | |||
| 3-Year Total Return | -70.43% | |||
| 5-Year Total Return | -43.00% | |||
| 52-Week High % Change | -64.14% | |||
| 52-Week Low % Change | 10.10% | |||
| Price | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.04 | |||
| 52-Week Low Price | $0.99 | |||
| 52-Week Low Price (Date) | Mar 03, 2025 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 413.10M | |||
| Enterprise Value | 153.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.55 | |||
| Earnings Per Share Growth | -42.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.34 | |||
| Price/Book (Q) | 0.87 | |||
| Enterprise Value/Revenue (TTM) | 0.88 | |||
| Price | $1.18 | |||
| Enterprise Value/EBITDA (TTM) | -1.32 | |||
| Enterprise Value/EBIT | -1.15 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 374.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 266 6000 | |||
| Address | 2 Tower Place South San Francisco, CA 94080 | |||
| Website | www.standardbio.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -76.16% | |||
| Profit Margin | -79.62% | |||
| Management Effectiveness | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -17.75% | |||
| Return on Equity | -- | |||
| Income Statement | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 173.51M | |||
| Total Revenue (TTM) | 174.43M | |||
| Revenue Per Share | $0.47 | |||
| Gross Profit (TTM) | 65.04M | |||
| EBITDA (TTM) | -116.00M | |||
| EBIT (TTM) | -132.86M | |||
| Net Income (TTM) | -138.89M | |||
| Net Income Avl. to Common (TTM) | -138.89M | |||
| Total Revenue Growth (Q YOY) | 65.74% | |||
| Earnings Growth (Q YOY) | -72.29% | |||
| EPS Diluted (TTM) | -0.55 | |||
| EPS Diluted Growth (Q YOY) | 64.03% | |||
| Balance Sheet | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 292.87M | |||
| Cash Per Share (Q) | $0.78 | |||
| Total Current Assets (Q) | 375.88M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 471.72M | |||
| Current Ratio (Q) | 5.704 | |||
| Book Value Per Share (Q) | $1.25 | |||
| Total Assets (Q) | 612.34M | |||
| Total Current Liabilities (Q) | 65.89M | |||
| Total Debt (Q) | 33.00M | |||
| Total Liabilities (Q) | 140.62M | |||
| Total Common Equity (Q) | 471.72M | |||
| Cash Flow | LAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 363.17M | |||
| Cash from Financing (TTM) | -102.62M | |||
| Net Change in Cash (TTM) | 116.32M | |||
| Levered Free Cash Flow (TTM) | -70.36M | |||
| Cash from Operations (TTM) | -143.45M | |||
